ConductScience.org, home

Paper42579877

Early EGFR Inhibition Triggers Actionable Tumor and Microenvironmental Remodeling in Lung Cancer.

Tan AC and 27 others. Cancer Res Commun, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Early EGFR Inhibition Triggers Actionable Tumor and Microenvironmental Remodeling in Lung Cancer. Papers, record 42579877. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42579877

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Early EGFR Inhibition Triggers Actionable Tumor and Microenvironmental Remodeling in Lung Cancer.
PubMed
Journal
Cancer Res Commun
PubMed
Year
2026
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-08-28
PubMed

Authors28

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Tumor MicroenvironmentMajor topic
Lung NeoplasmsMajor topic
GefitinibMajor topic
Carcinoma, Non-Small-Cell LungMajor topic
Protein Kinase InhibitorsMajor topic
Humans
ErbB Receptors
Female
Male
Middle Aged
Aged
Mutation
Neoadjuvant Therapy
Adult

Source PubMed

Download CSV of topics

Grants3

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
NMRC/TCR/007-NCC/2013National Medical Research Council (NMRC)PubMed
NMRC/CSA/007/2016National Medical Research Council (NMRC)PubMed
Fellowship 2018International Association for the Study of Lung Cancer (IASLC)PubMed

Source PubMed

Download CSV of grants

References62

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
137937763Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC.N Engl J Med2023https://conductscience.org/library/papers/37937763PubMed
231194613Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study.J Clin Oncol2019https://conductscience.org/library/papers/31194613PubMed
330242021A High-Throughput Immune-Oncology Screen Identifies EGFR Inhibitors as Potent Enhancers of Antigen-Specific Cytotoxic T-lymphocyte Tumor Cell Killing.Cancer Immunol Res2018https://conductscience.org/library/papers/30242021PubMed
434278827Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA.Future Oncol2021https://conductscience.org/library/papers/34278827PubMed
524384493Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint.Lancet Oncol2014https://conductscience.org/library/papers/24384493PubMed
631413010Combination of Metformin and Gefitinib as First-Line Therapy for Nondiabetic Advanced NSCLC Patients with EGFR Mutations: A Randomized, Double-Blind Phase II Trial.Clin Cancer Res2019https://conductscience.org/library/papers/31413010PubMed
716670306OX40-OX40 ligand interaction through T cell-T cell contact contributes to CD4 T cell longevity.J Immunol2006https://conductscience.org/library/papers/16670306PubMed
829335443Elucidating the genomic architecture of Asian EGFR-mutant lung adenocarcinoma through multi-region exome sequencing.Nat Commun2018https://conductscience.org/library/papers/29335443PubMed
924078774Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.Cancer Discov2013https://conductscience.org/library/papers/24078774PubMed
1031061481Determining cell type abundance and expression from bulk tissues with digital cytometry.Nat Biotechnol2019https://conductscience.org/library/papers/31061481PubMed
1137649478Tumor-associated macrophages mediate resistance of EGFR-TKIs in non-small cell lung cancer: mechanisms and prospects.Front Immunol2023https://conductscience.org/library/papers/37649478PubMed
1231486833
Effect of Metformin Plus Tyrosine Kinase Inhibitors Compared With Tyrosine Kinase Inhibitors Alone in Patients With Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: A Phase 2 Randomized Clinical Trial.
JAMA Oncol2019https://conductscience.org/library/papers/31486833PubMed
1315173831Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40.Nat Rev Immunol2004https://conductscience.org/library/papers/15173831PubMed
1429045514Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy.Ann Oncol2017https://conductscience.org/library/papers/29045514PubMed
1529871672Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches.J Immunother Cancer2018https://conductscience.org/library/papers/29871672PubMed
1619097774New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).Eur J Cancer2009https://conductscience.org/library/papers/19097774PubMed
1722753915Tumor response and toxicity of neoadjuvant erlotinib in patients with early-stage non-small-cell lung cancer.J Clin Oncol2012https://conductscience.org/library/papers/22753915PubMed
1835183043Correlation between treatment effects on response rate and progression-free survival and overall survival in trials of targeted therapies in molecularly enriched populations.ESMO Open2022https://conductscience.org/library/papers/35183043PubMed
1926313928Escher: A Web Application for Building, Sharing, and Embedding Data-Rich Visualizations of Biological Pathways.PLoS Comput Biol2015https://conductscience.org/library/papers/26313928PubMed
2037340841Tumor Microenvironment Modulation by Neoadjuvant Erlotinib Therapy and Its Clinical Impact on Operable EGFR-Mutant Non-Small Cell Lung Cancer.Cancer Res Treat2024https://conductscience.org/library/papers/37340841PubMed

See all 62 referencesDownload CSV of references

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
EGFR1956PubTator's text mininghttps://conductscience.org/library/genes/1956

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Cited by
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42579877

GET https://conductscience.org/api/papers/v1/42579877/authors?page=2